We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.02 | -0.43% | 4.65 | 4.69 | 4.72 | 4.78 | 4.60 | 4.69 | 3,689,738 | 00:58:28 |
GAITHERSBURG, Md., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter financial and operating results following the close of U.S. financial markets on Tuesday, August 8, 2017.
Conference call details are as follows:
Date: | Tuesday, August 8, 2017 |
Time: | 4:30 p.m. U.S. Eastern Time (ET) |
Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
Passcode: | 15614203 |
Webcast: | www.novavax.com, "Investors"/ "Events" |
Conference call and webcast replay:
Dates: | Starts at 7:30 p.m. ET, August 8, 2017 until 7:30 pm ET, August 15, 2017 | |
Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
Passcode: | 15614203 | |
Webcast: | www.novavax.com, "Investors"/ "Events", until November 8, 2017 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor Relations
ir@novavax.com
240-268-2000
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506
Media
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com
212-845-4271
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions